A transformational new treatment for multiple sclerosis (MS) has been approved by the EU agency responsible for regulating new drugs. This is the result of over three decades of research in Cambridge.
Although approved for use in EU, the drug has not yet been assessed by the National Institute for Health and Care Excellence (NICE) for the treatment of MS in the UK.
In recognition of the new treatment, the University of Cambridge has produced a video which explores the history of the drug, showing the many challenges as well as successes experienced during the course of this development.
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